entertainment -WSS

entertainment

author：explore 2025-09-29 20:52:31 - browse：41

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： 7 people shot in DC, police say

leisure time

WSS

FDA clears Verve to begin U.S. study of gene

Inside the fall of star MIT scientist David Sabatini

Readout LOUD podcast: Live from the 2023 STAT Summit

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

New case study details death in closely watched Alzhiemer's trial

Grail is spending more than ever lobbying Congress

hotspot

entertainment

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

J&J lung cancer data amount to new salvo against AstraZeneca

Apple is now the first public company to be valued at $3 trillion

Why is France rioting? What to know about the fatal police shooting of Nahel M

After affirmative action ruling, medical educators look to 'holistic review'

Doctor appointment wait times are getting worse

Hollywood unions extend contract negotiations for actors

4th of July breaks record for highest global temperature ever measured

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout LOUD podcast: Live from the 2023 STAT Summit

explore

Australia's humpback populations rebound raising hopes of marine scientists

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Grail is spending more than ever lobbying Congress

Grail is spending more than ever lobbying Congress

STAT Readout: Friday, Oct. 20 biotech updates

PhRMA sues HHS over Medicare drug price negotiation

leisure time

leisure time

Wikipedia

focus